Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results

IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced its full year and Q4 2024 financial results. Søren Tulstrup, President and CEO, Hansa Biopharma...